John J. Borer, III
President, Senior Managing Director, Head of Investment Banking
Rodman & Renshaw LLC
John Borer is the founder and senior
manager of Rodman, a member of the Commitments,
Investment Policy and Management Committees and
a member of the Board of Directors of the firm.
In addition to his administrative responsibilities,
he is active in the marketing and execution of
transactions. Borer has extensive experience in
transactions involving public and private underwritten
offerings of equity and debt for middle market
companies, as well as in the areas of corporate
restructurings and mergers and acquisitions. Prior
to his positions with Rodman & Renshaw, Inc.,
Borer was Senior Vice President and Investment
Manager in the New Business Development office
of Security Pacific Business Credit Inc., where
he worked for eight years. Prior to joining Security
Pacific Business Credit Inc., he spent five years
with Barclays American Business Credit in its
Los Angeles office. Borer received his B.A. in
Economics from the University of California at
Davis and his J.D. from Loyola Law School in Los
Angeles.
Nancy T. Chang, Ph.D.
Chief Executive Officer
Tanox, Inc
Dr. Nancy T. Chang is one of the co-founders
of Tanox, Inc and has served as President since
in March 1986 and as Chief Executive Officer since
June 1990. She also served as our Chairman of
the Board from March 1986 until November 2003.
From 1986 to 1992, Dr. Chang served as an Associate
Professor at Baylor College of Medicine in the
Division of Molecular Virology. Between 1981 and
1986, Dr. Chang was employed by Centocor, Inc.,
serving as the Director of Research, Molecular
Biology Group, from 1984 to 1986. From 1980 to
1981, she was employed by Roche Institute of Molecular
Biology. Dr. Chang received her Ph.D. in Biological
Chemistry from Harvard University.
Li Chen, PhD
Chief Scientific Officer,
Roche R&D Center China
In April 2004, Li Chen, Ph. D, was appointed the Head of Research at Roche R&D
in Shanghai China. In this position, Li is responsible
for establishment of research infrastructure and
recruitment of scientific staff, management of research
portfolio at Roche's 5th R&D center. He serves as
member at the Scientific Board of Roche R&D China,
chaired by Dr. Lee Babiss. Before this assignment,
Li was a Senior Research Leader and Head of High
Throughput Chemistry at Hoffmann-La Roche Inc in
Nutley, New Jersey. His responsibilities included
evaluation, development and implementation of high
throughput chemistry technology (HTCT), and management
of high throughput medicinal chemistry (HTMC). During
his tenure at Roche Nutley Research Center, Li severed
as a member of Chemistry Management Team, Roche
Patent Coordination Committee and Joint Research
Management team of Roche collaborations. He was
the founder of New Lead Chemistry Initiative to
create high quality drug leads. He has led many
drug discovery projects including MC-4 agonist,
CDC-7 inhibition and CDK1 inhibition project. Li
is a key contributor to the discovery of R411, a
drug in Phase II trial for the treatment of asthma.
Li joined Roche in 1992 after received his Ph. D.
in Organic Chemistry at Iowa State University under
the direction of Professor George Kraus.
Peiling Cheng, PhD
Principal
Pharmaceutical Sourcing Partner, Inc. (PSP)
Dr. Peiling Cheng is the founder and principal of Pharmaceutical Sourcing Partner, Inc. (PSP). She has 10 years of manufacturing experience with top global companies.
Prior to PSP, Dr. Cheng held various positions in the manufacturing division of Merck & Co. While at Merck & Co., Dr. Cheng held various positions of responsibility and leadership in the Technical, Quality and Regulatory Groups and had hands-on experience in pharmaceutical operations. She led multi-functional teams in reducing atypical manufacturing events and improving manufacturing processes by identifying root causes of inconsistent processes. Dr. Cheng also worked in the Business Process Engineering group of Merck specializing in re-engineering core business processes to improve organizatioal effectiveness. Dr. Cheng played leadership roles in the re-engineering effort for the clinial trial and supply chain management processes.
Before joining Merck, Dr. held technical positions at Ciba-Geneva and Warner-Lambert as a laboratory scientist in the areas of API sourcing, ANDA filing, and regulatory compliance.
Dr. Cheng then co-founded CXZ Pharmaceuticals, later renamed to PSP specializing in sourcing pharmaeutical products from China and working with quality Chinese suppliers on their manufacturing processes and cGMP certifications. PSP is a company based in Princeton, NJ with offices in Shanghai and Shenzhen with key clients in the US, Canada and the European Union Countries. PSP's main focus is partnering with clients to identify cost saving opportunities by reaplacing higher cost APIs with quality lower cost alternatives from China. PSP's core compentency is its in-depth understanding of the cGMP requirements and its ability in assisting Chinese become cGP compliant. PSP also advises Chinese pharmaceutical companies on North American and EU market trends and product development strategies and frequently speaks at conferences and forums.
Dr. Cheng holds an Ph.D. in Chemistry from Arizona State University.
Born and raised in China, trained in the US, Dr. Cheng now focuses her effort in parntering and building bridges bewteen Western and Chinese pharmaceutical companies.
James E. Foley, Ph.D.
Vice President, Business Development- Japan/International
Corporate and Business Development
Bristol-Myers Squibb Company
Dr. Foley is a Vice President in Bristol-Myers
Squibb's corporate and business development group
with primary responsibility for the Asia/Pacific
area. Dr. Foley rejoined Bristol-Myers Squibb in
his current position April 1, 2002 after spending
10 years at SmithKline Beecham and GlaxoSmithKline
in a similar role.
Dr. Foley's career in the pharmaceutical industry
began in 1977 at the Squibb Institute of Medical
Research (E. R. Squibb and Sons). After 12 years
in R&D, he joined the Department of Licensing
and Business Analysis at Squibb and relocated
to Tokyo, Japan in 1989 to manage the company's
licensing activities related to Japanese pharmaceutical
companies. Dr. Foley remained with Bristol-Myers
Squibb after the merger and joined SmithKline
Beecham in 1991 where he remained based in Tokyo
until 1995.
Dr. Foley has served on the Boards of Directors
of St. Peter's School (Philadelphia), Sosei &
Company, Inc. (Tokyo), the Japan-America Society
of Greater Philadelphia and the New York Pharma
Forum. He also serves on an Advisory Committee
for the Haub School of Business (St. Joseph's
University, Philadelphia) and chairs the Japan-
Philadelphia Health Sciences Dialogue, an annual
meeting held in Philadelphia addressing healthcare
issues/solutions in the US and Japan.
Born November 5, 1944, Dr. Foley holds a Ph.D. in
Physiology and Pharmacology from Thomas Jefferson
University, where he received a graduate fellowship
from the Charlotte Drake Cardeza Foundation for
Hematologic Research in the laboratory of Dr. Allan
J. Erslev (Director and Cardeza Research Professor
of Medicine), and a BA in Biology and Chemistry
from Rutgers University. He was a NIH Post Doctoral
Fellow from 1975 to 1997 in the Laboratory of Hematopharmacology
under Dr. James W. Fisher, Professor and Chairman,
Department of Pharmacology, Tulane University School
of Medicine in New Orleans.
Nicholas Franco, PhD, MBA
Global Head of BD&L Primary Care
Novartis Pharmaceuticals
Nicholas Franco originally trained as a Biochemist at McGill University
in Montreal Canada and pursued basic research
in protein structure at the Montreal Clinical
Research Institute for over 6 yrs. After completing
an MBA, he joined Novartis in Montreal in 1991
and has held various position of increasing responsibility,
both in an affiliate and in Headquarters, in Sales,
Product Marketing, New Product Development, General
Management and Business Development and Licensing
both Alliance Management and Negotiation). Nicholas
is currently Global Head of BD&L Primary Care
and a member of the Pharma Leadership Team in
Basel, Switzerland.
Xiaodi Guo, Ph.D.
Vice President of Product Development
Abrika Pharmaceuticals, Inc.
Dr. Xiaodi Guo holds
a Vice President position at Abrika Pharmaceuticals,
an emerging specialty pharmaceutical company in
Florida. Dr. Guo started the company's R&D function
and research/manufacturing facility two years
ago from scratch. Currently, Abrika has about
45 people with 20 headcounts in R&D. At his current
position, Dr. Guo is responsible for the company's
own product development, intellectual property
building and new technology assessment/development,
and outsourcing activities. Prior to the current
position, he served as a Team Leader/Principal
Scientist at Barr Laboratories Inc, and a Senior
Scientist and then Manager of Drug Delivery Sciences
at Shire Laboratories Inc. Dr. Guo has more than
30 publications and is the inventor of more than
ten patents. He is a frequent speaker in pharmaceutical
and life science related meetings both in US and
China and also an adjunct professor at Shanghai
Institute of Pharmaceutical Industry, China. Dr.
Guo received a B.S. degree in Pharmacy from China
Pharmaceutical University, China (1984); a M.S.
degree in Pharmaceutics from Shanghai Institute
of Pharmaceutical Industry, China (1987); and
a Ph.D. degree in Industrial Pharmacy from the
University of Texas at Austin, USA (1996).
Yongtai Hou Ph.D.
Life Science R&D Head
CWGC Group/Shanghai Pharmaceutical Group
Dr Hou has
been the head of Life Science R&D of CWGC group
since 2000. In this capacity, Dr Hou has full
responsibility for all Life Science R&D activities,
and played critical role in obtaining approvals
of 2 new drug and 3 nutraceutical applications
by SDA in the past 3 years. Currently CWGC Life
Science has two new drug applications under SDA
review. Other CWGC projects under development
include: 5 pipeline products/technologies, 1 formulation,
and 2 nutraceuticals. Dr Hou is also in charge
of CWGC/Shanghai Pharmaceutical group's Life Science
strategic partnership, merge and acquisition,
and venture investment activities. Prior to CWGC,
Dr Hou was a professor in molecular pharmacology
at Chinese Academy of Science. He has published
numerous peer-reviewed articles in leading scientific
journals, and was a frequent speaker at various
scientific meetings. Dr Hou earned a BS in biology
from Nanjing University, a MS in Microbiology
and a PhD in Molecular biology from Ohio State
University. Dr Hou also received postdoctoral
training in Pharmacology at University of Pennsylvania
and executive MBA training from University of
British Columbia. Before retuning to China, he
was an assistant professor at the University of
Michigan.
Kewen Jin M.D.
Consultant, Eli Lilly China,
Managing Partner, Aura Partners Limited
Aura Partners Limited - A Shanghai based consultancy serving global life science industry and investment companies in business development and licensing, R&D out-sourcing, project financing. Current and past clients include Eli Lilly, Shanghai Pharmaceutical Group (the largest Chinese pharma company), major US and Chinese investment funds and consulting firms, several US and China pharma, biotech, devices, and healthcare service companies.
Dr. Kewen Jin is currently a consultant and investment advisor for life science industry companies, based in Shanghai, China. Formerly a marketing, business development, and international operation executive at Wyeth (1992-2000, formerly American Home Products; Associate Director, Global Strategic Marketing (1992-96); Director of China Operations(1996-1998); Head of pharmaceutical business for Northern China(1999-2000)); COO/President of a medical technology start-up in China (2000); General Manager of Sales & Marketing for ChinaCare Group, the healthcare subsidiary of a major Asian conglomerate (2001). Trained in medicine (Shanghai Second Medical University); molecular biology (Rockefeller University); health economics (University of Pennsylvania); and finance (Columbia University)
Lei Jin, Ph.D.
Founder & CEO
GeneScience Pharmaceutical Inc
In 1994,Dr. Lei Jin, a former Genentech researcher,
came back to China to pioneer the Growth hormone
development in China. In 1997,GeneScience Pharmaceutical
Inc. was founded in Changchun, China by him in
Changchun High-tech Development Zone. In 2002,GeneSciencei’s
recombinant human growth hormone (rhGH, Jintropin)
has captured about 67% of China’s growth hormone
market. GeneScience is one of the largest biopharmaceutical
companies in China now. It has three products
on the market and more than ten products on the
development pipeline. GeneSciencei’s production
facility locates in Changchun High-tech Development
Zone, it covers more than 20,000m2 of land and
has 11,000m2 of floor space. It is one of the
largest and finest equipped biopharmaceutical
production facilities in China.
Frank Kung, Ph.D., M.B.A.,
Managing General Partner
BioAsia Investments, LLC
Dr. Kung is the founding
Managing Member of BioAsia Investments, LLC (BioAsia),
a healthcare/biotechnology venture capital management
firm in Palo Alto, California. BioAsia, formed
in 1996, invests primarily in life sciences companies,
and assists these companies in the development
and commercialization of their products. Its current
portfolio includes more than 60 private and public
biotechnology companies in the areas of biopharmaceuticals,
specialty pharmaceuticals, and medical devices.
BioAsia led in more than 2/3 of all venture investments
it made in the past 7 years, and usually before
major rounds of financing led by large funds.
Dr. Kung started his career in the biotechnology
industry in 1979 when he joined Cetus Corporation.
He later co-founded Cetus Immune Corporation in
1981, which was acquired by its parent company
in 1983. In 1984 he co-founded Genelabs Technologies,
Inc. (NADSAQ: GNLB) where he served as Chairman
and CEO until 1995. During his tenure in Genelabs,
he brought the company public in 1991, and built
it to a 175 employee international biotech company
with operations in the United States, Belgium,
Singapore, Switzerland and Taiwan.
Dr. Kung received
his B.S. in chemistry from the National Tsing
Hua University in Taiwan, his Ph.D. in molecular
biology and M.B.A. from the University of California,
Berkeley. He received the Best Use of Technology
Award from the Governor of California, the Entrepreneur
of the Year Awards from Ernst and Young, and the
Asian Business League. He also served on the board
of directors of the Emerging Company Governing
Body of the Biotechnology Industry Organization
(BIO); Mt. Jade Science and Technology Association,
West Coast; and the Asian American Manufacturing
Association. He was appointed by the U.S. Secretary
of Health and Human Services as a voting member
of the National Biotechnology Policy Board. Dr.
Kung currently serves on the board of directors
of a number of emerging healthcare and biotechnology
companies.
Jong-Dae Lee, J.D.
Chief Executive Officer
China HealthCare Holdings Limited
Mr. Lee is an experienced international lawyer and investment banker. He
received his undergraduate degree in economics from
Haverford College, Pennsylvania, and later obtained
his Doctor of Jurisprudence from Georgetown University,
Washington, D.C. He began his practice in Washington,
D.C. where he specialized in international trade
matters, and moved to Hong Kong in 1988 to join
Coudert Brothers. As a partner of Coudert Brothers,
he practiced in the corporate and finance areas
focusing on regional cross border transactions,
often involving China. He left full time law practice
in 1997 to become a senior investment banker for
Rabobank International, Citigroup, and certain other
financial institutions, with broad responsibilities
for complex cross-border transactions. He serves
on the Executive Committee of Lee International
IP & Law Group and is an advisor to and director
of several corporations.
Bin Li, Ph.D., MBA
Equity Research Analyst, Pharmaceuticals
Merrill Lynch & Co., Inc.
Bin is an equity research analyst at Merrill Lynch, covering
pharmaceutical industry. As a stock analyst, he
provides investment opinions to institutional
and individual investors. His research covers
topics such as company financial status, R&D pipeline
updates, product market assessments, physician
surveys, prescription trends, price analysis,
patent and legal challenges, FDA regulatory policies,
and legislative/political environment. He coordinates
research efforts of Merrill Lynch Global Pharmaceuticals
Team in the U.S., UK, Germany, Japan, Canada,
Australia, India, and other regions. Bin received
his Ph.D. in biochemistry and M.B.A. from New
York University. Prior to his current position
at Merrill Lynch, he worked at Goldman Sachs and
at Merck Research Laboratories as a research scientist.
James Li, MD
Director
Merck's Asia Franchise
Dr. James Li currently holds the position of Merck's
Asia Franchise Director - Hypertension, Human
Health Division and is responsible for the 100
million dollar plus franchise for Merck's Asia
operations.
Dr. Li is a known expert in Asia Pharmaceutical
Industry specializing in clinical research, regulatory
affairs, product development/access and marketing.
He has been an invited author, speaker and guest
consultant for a number of government regulatory
agencies, academic institutes and industry associations
on region's clinical, regulatory access and marketing
issues.
James started his career with Merck Research
Laboratories in 1991 and went through various
assignments in basic and clinical research. In
1994, he joined Merck Vaccine Division Asia Pacific
Operations, based in Hong Kong, and was responsible
for division's clinical research and regulatory
affairs in the region. From 1996 to 2000, James
joined Merck's China Operations as the Medical
Director, where he successfully developed a first
class professional medical team and implemented
a development plan that integrated and supported
Merck business strategy for China. James moved
back to New Jersey in 2000 and was appointed as
the Asia Pacific Regional Director, Clinical Research
and New Products, supporting both clinical research
as well as new product marketing for the region.
He has been since a member of various Merck's
Worldwide Business Strategy Teams and Global Marketing
Teams. In 2003, James took the current assignment
as the Asia Franchise Director for Merck's Hypertension
Franchise.
James received his Medical Degree from
Shanghai Medical University, completing an internship
in Internal Medicine and a fellowship in Oncology,
followed by a Master of Science degree in Microbiology
from the University of Montana.
Jeffery Z. Li, Ph.D., MBA
Partner
HT Pharma
HT Pharma is a strategic consulting firm dedicated to US-China Pharma/Life Science partnership opportunities. Dr. Li's healthcare experience ranges from academic research, biotech start-up to marketing and business development with fully integrated pharmaceutical companies. Dr. Li received his doctoral and post-doctoral training from Harvard and published various peer reviewed articles in leading scientific journals. He held several management positions with increasing responsibilities at Warner-Lambert Company; was a founding member of Enzyme Design, Inc, a biotech company; a founding partner at ESP Partners, LLC, a healthcare consulting and investment firm; Vice President and a member of founding team of ESP Pharma, a specialty pharmaceutical company.
Dr. Li holds a Doctor of Science from Harvard, an MBA from the University of
Michigan, a BSc in Physics and a BSc in Biology from Tsinghua University in Beijing, China
Zhongyuan Li, Ph.D.
Chairman
China HealthCare Holdings Limited
Dr. Li received his PhD. in Mathematics from the University of Michigan
at Ann Arbor and subsequently worked as an Assistant
Professor of Mathematics at the Massachusetts Institute
of Technology ("MIT"), where he was consecutively
awarded research grants from the National Science
Foundation. After MIT, he held senior positions
with a number of major international investment
banks, including Bankers Trust Company, Salomon
Brothers, and IBJ Asia and had extensive experience
in capital raising and risk management. In late
1996, he was in charge of building up the capital
markets and derivative businesses in multi-asset
classes in Northern Asia and was a Director of Rabobank
International before setting up a financial and
technology investment firm. Dr. Li is also an independent
non-executive director of Hong Kong Construction
(Holdings) Limited, a company listed on the Hong
Kong Stock Exchange.
Robin Yuanhong Ma, PhD
President
Clingenix
Dr. Ma's technical and operational experience spans academia, biotechnology,
and the pharmaceutical industry. Dr. Ma has over
18 years of research experience in molecular genetics
of cardiovascular disease and metabolic diseases.
Prior to joining Clingenix, Dr. Ma was the program
director of diabetes and cardiovascular disease
at DNA Sciences. She also served as a program manager
at Parke-Davis, a division of Warner Lambert, and
as an assistant professor of medical genetics at
the University of British Columbia in Vancouver,
Canada. Dr. Ma received her PhD from the University
of California, Los Angeles in 1988. Dr. Ma has published
over 45 scientific papers, abstracts, and patent
applications.
Raymer McQuiston
Partner
Torys
Ray McQuiston's practice places emphasis
on mergers and acquisitions, finance, securities
and technology law. He advises public and private
companies in tender offers, rights and warrants
offerings, proxy solicitations, acquisitions,
leveraged financings, cross-border transactions,
securitizations, initial public offerings, private
placements and secured and unsecured Rule 144A
transactions. He counsels both start-up and established
technology companies on intellectual property
issues, tax structuring, venture capital, recapitalizations
and joint ventures, and he counsels private and
public companies on insurance matters (including
alternative risk and residual value insurance
products).
Mr. McQuiston is a member of the New York Software
Industry Association and the International Bar
Association. He was admitted to the New York Bar
in 1988. He earned his J.D. (cum laude) from Syracuse
College of Law and B.Sc. from University of Michigan.
David R. Risinger, CFA
Senior Analyst, U.S. Major Pharmaceuticals
Merrill Lynch & Co., Inc.
David covers the US Pharmaceutical Industry for Merrill Lynch's Equity
Research Department in the United States. Prior
to joining Merrill Lynch as a First Vice President,
David spent eight years in pharmaceutical and
healthcare equity research at Morgan Stanley &
Dillon Read. He was a top-ranked Healthcare Distribution
& IT analyst in the Institutional Investor poll
in 2000, 2001 and 2002. In 1998 and 1999, David
was ranked in the Reuters Survey for his research
in the healthcare industry.
David graduated from Bucknell University
in 1991 with a B.A. in political science and received
his CFA Charter in 1995
David has won various awards in:
June 2000 #2 TheStreet.com Equity 2000 Analyst
Ranking
October 2000 #2 Institutional Investor 2000 All-America
Research Team
April 2001 #1 Greenwich Ranking
October 2001 #2 Institutional Investor 2001 All-America
Research Team
October 2002 #3 Institutional Investor 2002 All-America
Research Team
Victor Shi, Ph.D.
Co-Founder and Senior Vice President of Corporate Development
Bridge Pharmaceuticals
Dr. Victor Shi brings broad life science industry
and international experience drawing from small
and large companies, management consulting, venture
capital investment and research and development.
He has twelve years of experience (including seven
years living in Asia) in life science business
development, transactions, startup, and corporate
partnership. Over the years, he has built extensive
network with life science companies and institutions,
investment groups, and government agencies in
China and the Asia Pacific.
Victor currently is co-founder and Senior Vice
President of Corporate Development at Bridge Pharmaceuticals,
a spin-off company of SRI International, which
focuses on helping US pharmaceutical and biotech
companies to outsource pre-clinical development
to Asia. Bridge's business is an extension of
Victor's previous consulting firm, Discovery Resources
Group.
Previously Victor was Vice President of Corporate
Development at GenoSpectra, a biochip and drug
discovery tools company located in the San Francisco
Bay Area. He is also an advisor to A. M. Pappas
& Associates, a life science consulting and venture
capital firm, where he previously started and
directed its Asia investment and consulting business.
During his tenure as a management consultant,
he worked on behalf of Quintiles Transnational,
Johnson & Johnson, Pharmacia & Upjohn, Keravision,
BioChem Pharma, Genetronics, Chiroscience, among
others, in Asia development and market entry.
As an entrepreneur, Victor has founded and operated
two startup companies, in addition to being on
the founding team of GenoSpectra. He was responsible
for raising over $40 million venture funds in
aggregate from major US and international life
science investors.
In addition to his business experience, Victor
also has a strong scientific background, being
a former cancer research scientist at Merck Research
Laboratories and a faculty member at the National
University of Singapore Faculty of Medicine. He
has published over 30 scientific papers and has
been an invited speaker at a number of life science
business conferences in US and Asia. He received
his Bachelor's degree from the University of Science
and Technology of China, and M.S. and Ph.D. degrees
from the University of Rochester School of Medicine,
New York.
David Y. Sun, MBA, M.S.
Senior Vice President of Business Development and Marketing.
Capital Biochip Corporation
Most recently, Mr Sun was Interim Chief Business Officer of BioAgri,
Vice President of Business of Xeotron, all U.S.
biotech compaines. From 1990-2001, David assumed
Sr. managerial Corporate Business Development,
Marketing and R&D functions with Amgen, the world's
largest Biopharmaceutical company, Dendreon and
Motorola Life Sciences. He help crafted or negotiated
transactions with companies in U.S., Europe and
Japan valued >$600 millions. He holds a MBA in
Finance from the Anderson School at University
of California, Los Angeles. His technical training
includes a B.S. from Lanzhou University, M.S.
from University of Toledo and Ph.D. training (candidacy)
from Ohio State University, all in Molecular &
Cellular Biology.
Jianbo Sun, M.D., PhD
Senior Vice President
Beijing Tri-prime Genetic Engineering Co., Ltd
Dr. Sun
is the Senior Vice President of Beijing Tri-prime
Genetic Engineering Co., Ltd. Where he is in charge
of technology and business development. Prior
to joining Beijing Tri-prime Genetic Engineering,
Dr. Sun served as a Research Scientist at Ortho-Clinical
Diagnostics, a Johnson & Johnson Company, where
he conducted research works on developing new
molecular diagnostics. As a result of his work
at Ortho-Clinical Diagnostics, two patents were
filed.
Dr. Sun was a Postdoctoral Fellow at the National
Laboratory of Genetics Fudan University, Shanghai,
where he did research works on anti-tumor Parvoviruses.
He earned his M.D. and PhD in Molecular Biology
from Institute of Preventative Medicine. He also
holds a Master's Degree in Radiology and a Bachelor's
Degree in Medicine.
Miranda Tan
President and Founder
Excite Media Group, LLC
Miranda Tan is the President and Founder of EMG. She guides the overall direction
of the firm. Prior to founding Excite Media Group,
Miranda founded ExcitePR, a $2 MM strategic consulting
and public relations company and worked on numerous
technology and Internet-related public relations
accounts for both start-ups and established companies
on both national and international campaigns. Aside
from ExcitePR, Miranda was the vice president and
a member of the senior management team of the New
York office of a $15 MM public relations firm based
in Palo Alto. She has represented fortune 500, public
and private companies and conducted numerous product/company
launches, analyst tours, events, tradeshows and
national and international media tours.
Miranda received her Bachelor of Science from
Cornell University and Juris Doctorate from St.
John's University School of Law. She is admitted
under the New York Bar. Prior to her career in
public relations and marketing, Miranda was a
corporate attorney at a mid-sized firm in Pennsylvania.
Stella Xu
Global Alliance Director
Roche Pharma Partnering
Dr. Stella Xu is a Global Alliance
Director with Roche Pharma Partnering where she
currently manages multiple alliances with biotechs
around the world. Her responsibilities include
leading due diligence assessment and supporting
negotiation of new licensing opportunities, integrating
new alliances into the Roche Pharmaceuticals development
portfolio, as well as managing relationships with
alliance partners.
Stella joined Roche from McKinsey & Company,
a management consulting firm that provides strategic
advices to the top management of global business
leaders. At McKinsey, she led consulting engagements
with biopharmaceutical clients in areas ranging
from R&D strategy, marketing & sales, to corporate
development. Prior to this position, Stella was
a research scientist with Isis Pharmaceuticals.
Stella received her BS in Biophysics from Peking
University; her Ph.D. in Biochemistry, Molecular
Biology and Cell Biology from Northwestern University;
and an executive MBA training at the Kellogg School
of Management, Northwestern University.
Xi Zhao-Wilson, Ph.D., MBA
Chief Executive Officer, Founder, Director
BioMarker Pharmaceuticals, Inc.
Dr. Zhao-Wilson is Founder, CEO and Director of BioMarker Pharmaceuticals Inc. The company is developing a new class of therapeutics and pharmaceuticals to prevent and treat ageing related disease and slowing down the rate of aging. The company has developed a genomic-based, reliable, robust and predictive assay system based on the only intervention, which demonstrated the extension of healthy lifespan in animal and prevention of cancer, heart disease, neurodegenerative disease and diabetes.
Dr. Zhao-Wilson has more than fifteen-years experience as a senior executive of start-up, early stage and established companies in the biotech industry. Prior to BioMarker, she was a corporate development executive at Aviron, a biopharmaceutical company that recently merged with MedImmune. She was a founder and CEO of InCell, a biotech company. Dr. Zhao-Wilson served as board director and senior executive officer at Baekon, a biotech company.
Dr. Zhao-Wilson is Professor at the Chinese Academy of Preventative Medicine. She was a Research Scientist at Stanford University Medical Center where she conducted research in the field of gene regulation in various cancers that are related to steroid hormone receptors.
Dr. Zhao-Wilson has been awarded four U.S. patents and has published numerous research articles and book chapters. She has successfully obtained research funding through an SBIR Grant from the U.S. Department of Health and Human Services and an award from the Katharine McCormick Fund. She also lectured extensively at international research institutions including the U.S. National Institutes of Health, the Max-Planck-Institute in Germany and at numerous universities in the U.S., China, and European countries.
Dr. Zhao-Wilson received her M.S. in molecular genetics and cell biology from the Institute of Cell Biology, Chinese Academy of Sciences, and her Ph.D. in Cellular and Developmental Biology from The Ohio State University. Her MBA, from Fisher School of Business, MIIS focused on international business management.
Steve Yang, Ph.D.
Senior Director
Strategic Management Group of Pfizer
Dr. Steve Yang is a Senior Director in Strategic
Management Group of Pfizer Global Research and Development
(PGRD). His main responsibilities include providing
strategic advice and consulting service to the senior
executives of the Pfizer R&D organization. He has
extensive experience in strategic planning, portfolio
management, business and corporate development,
and merger and acquisition. Since Steve joined Pfizer,
he played key roles in several projects such as
implementation of a global initiative focusing on
reducing compound attrition in Discovery and early
clinical stage, integration planning and coordination
for Pfizer-Pharmacia merger, and transition management
of Pfizer’s recent acquisition of Esperion Therapeutics.
Dr. Yang is a recipient of the Pfizer Global Research
and Development (PGRD) Achievement Award. He is
also a member of Pfizer’s World Wide Discovery Leadership
Team. Prior to joining Pfizer, Steve was employed
by IntraBiotics Pharmaceuticals, an emerging biotech
company that focuses on developing novel antibiotics.
At IntraBiotics, Steve held positions of varying
responsibilities including Director of Corporate
Strategy and Senior Director of Corporate Development.
He was a part of the management team leading the
company’s IPO process in March 2000. Steve also
worked for Strategic Decisions Group (SDG), a boutique
management consulting firm specialized in strategy
consulting for Fortune 100 companies. At SDG, Steve
served clients in pharmaceutical and other capital
intense industries. He has project experience with
two major pharmaceutical companies in the areas
of portfolio management, process improvement, product
Go/No Go decision, as well as therapeutic area strategy.
Steve received his PhD in Pharmaceutical Chemistry
from the University of California, San Francisco.
He started his undergraduate study in Fudan University,
Shanghai, China and completed his BS Summa Cum Laude
in Biology from Michigan Technological University.
Zhi Yang, Ph.D.
Chairman & Co-Founder, Crimson Pharmaceutical Ltd.
General Partner, Bioveda Capital
Dr. Yang currently is a general partner and
executive director for BioVeda Capital, a venture
capital firm focusing on investment of biotechnology
in Asia Pacific and Worldwide. Dr. Yang serves
on the boards of several US biotech and pharmaceutical
companies. In addition, he is the associate editor
for American Health Today. Prior to join BioVeda,
Dr. Yang had three-year M&A experiences in Asia
with H&Q Asia Pacific and its investment arm,
Sinogen Inc. He had visited over hundreds of biotech
and pharmaceutical companies in the region and
was instrumental for the success acquisition of
several biopharmaceutical companies in China.
Dr. Yang has over 20 years of experience in biotechnology
and biosciences. He had held senior scientific
and management positions in variety of biotech
and pharmaceutical companies, which include Sinogen
International Ltd, Incyte Pharmaceuticals, Prolinx
Inc, BioChain, Sandoz pharmaceuticals, and Systemix
Inc. During his industrial stint, he had been
in many different positions such as interim CEO,
VP Business Development, VP of R&D, Director of
Molecular Biology, Group Leader and Senior/Principle
Scientist. Dr. Yang is also the principle inventor
for more than 10 international patents. Dr. Yang
holds a M.A. and Ph.D. in Biochemistry and Molecular
Biology from Harvard University. Walter Gilbert
(Nobel laureate) was the chairman of Dr. Yang's
thesis committee and Jack Strominger was his thesis
advisor. From 1988 to 1991, he was a senior associate
fellow and faculty member at Rockefeller University.
Dr. Yang obtained his B.S. in Virology from Wuhan
University in 1982. In the same year, he had been
admitted as a graduate student at Institute of
Virology, Chinese Academy of Medical Sciences.
Dr. Yang was among the first group of CASBEA students
to come to US to study biosciences.
Dan Zhang, MD, MPH, MBA
Head of Clinical Development
Sigma Tau Research Inc
Dr. Dan Zhang has led a distinguished career in healthcare-related industries. He is currently the Head of Clinical Development at Sigma Tau Research Inc, a US research arm of Sigma-Tau S.P.A., one of the largest pharmaceutical firms in Italy. At Sigma-Tau, Dr. Zhang manages the firm’s entire clinical development program, from clinical development, human safety and project management, ranging from Phase I to Phase IIIb, with four directors directly reporting to him.
Prior to Sigma-Tau, Dr. Dan Zhang was with Quintiles Transnational Corp. as the Vice President of the Greater China Area, responsible for the planning and implementation of business development strategies. Prior to this position, Dr. Zhang was the Vice President of Strategic Planning for the Greater China Area and the Director of Health Policy Business Development for Quintiles Benefit Inc.
Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., CIGNA Health Care, etc.
Through his research and consulting activities, Dr. Zhang has developed a unique working rapport with Chinese government agencies and academic institutions. Dr. Zhang was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. He is also a visiting professor at the Harbin Medical University of China. In addition, Dr. Zhang is an academic advisor and consultant for the Shanghai Medical University in the field of Pharmacoeconomic study and clinical trials.
Dr. Zhang received his pre-med training from Beijing University and received his M.D. from Peking Union Medical College. He continued his studies at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his studies at the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance.
Dr. Zhang has published several papers in the fields of medical research and health economics, and is a frequent speaker at various health care-related conferences.
Nathan Zhang, Ph.D., MBA,
President
Chipscreen Biosciences Co., Ltd.
Dr. Zhang got his Ph.D. degree in pharmacology
from the University of Pennsylvania and an MBA degree
from the University of Chicago. He was a senior
consultant for KPMG (New York), a senior manager
of Boston First Bank, and the managing director
of Delirium Technology (USA) in China. Dr. Zhang
is experienced in company management, marketing,
strategic alliance, merge and acquisition.
Xiaolin Zhou, S.J.D.
Senior Partner
JunHe Law Offices, New York
Mr. Zhou has 20 years' experiences in government work
and private practice. As the managing partner of the firm's
New York Office, Mr. Zhou specializes in international
business transactions and focuses on advising clients
in doing business in China. His clients include many Fortune
500 industrial and business corporations, banks, insurance
companies, foreign law firms and international organizations.
Mr. Zhou also regularly advises Chinese entities and individuals
on doing business in the U.S. Prior to entering private
practices, Mr. Zhou served for six years as the Head of
International Law Division, Department of Treaty & Law,
Ministry of Foreign Affairs of China. He also served as
consultant to the Chinese Delegation to the UN General
Assembly and Chinese delegate to the UN Legal Committee,
Outer-space Legal Subcommittee and UN Charter Committee.
Mr. Zhou participated in numerous international negotiations
and conferences and had experiences in handling major
judicial and arbitration cases involving Chinese government
agencies and enterprises in foreign courts and arbitral
tribunals. Mr Zhou has LLM and S.J.D. from Harvard University,
and a LL.M., Institute of Law, Chinese Academy of Social
Sciences in Beijing. He is also a Member of the State
Bar of New York and a Member of All-China Bar Association.
|
